Search research articles
Contact Us
Filters
Showing results (471-480 of 512) with videos related to
Page
of 52
Sort By:
Nature Genetics
|
September 8, 2015
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas
Francois Le Loarer, Sarah Watson, Gaelle Pierron, et al.
The Lancet. Haematology
|
December 12, 2018
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
Nicolas Delanoy, Jean-Marie Michot, Thibault Comont, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 23, 2020
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Vivek Subbiah, Luis Paz-Ares, Benjamin Besse, et al.
The European Respiratory Journal
|
September 29, 2018
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial
Guy Meyer, Benjamin Besse, Hélène Doubre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2025
Amivantamab Plus Lazertinib in Atypical <i>EGFR</i>-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2
Pascale Tomasini, Yongsheng Wang, Yongsheng Li, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2021
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
Laura Mezquita, Isabel Preeshagul, Edouard Auclin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2023
Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Naoual Menssouri, Loïc Poiraudeau, Carole Helissey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 30, 2020
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <i>BRAF</i>-Mutant Metastatic Non-Small Cell Lung Cancer
Sandra Ortiz-Cuaran, Laura Mezquita, Aurélie Swalduz, et al.
Journal for Immunotherapy of Cancer
|
February 17, 2022
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
Alessio Cortellini, Biagio Ricciuti, Victor R Vaz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 5, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA
Se-Hoon Lee, Shun Lu, Hidetoshi Hayashi, et al.
Page
of 52
Search research articles
Search
Showing results (471-480 of 512) with videos related to
Sort By:
Page
of 52
Nature Genetics
|
September 8, 2015
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas
Francois Le Loarer, Sarah Watson, Gaelle Pierron, et al.
The Lancet. Haematology
|
December 12, 2018
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
Nicolas Delanoy, Jean-Marie Michot, Thibault Comont, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 23, 2020
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Vivek Subbiah, Luis Paz-Ares, Benjamin Besse, et al.
The European Respiratory Journal
|
September 29, 2018
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial
Guy Meyer, Benjamin Besse, Hélène Doubre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2025
Amivantamab Plus Lazertinib in Atypical <i>EGFR</i>-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2
Pascale Tomasini, Yongsheng Wang, Yongsheng Li, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2021
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
Laura Mezquita, Isabel Preeshagul, Edouard Auclin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2023
Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Naoual Menssouri, Loïc Poiraudeau, Carole Helissey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 30, 2020
Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <i>BRAF</i>-Mutant Metastatic Non-Small Cell Lung Cancer
Sandra Ortiz-Cuaran, Laura Mezquita, Aurélie Swalduz, et al.
Journal for Immunotherapy of Cancer
|
February 17, 2022
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
Alessio Cortellini, Biagio Ricciuti, Victor R Vaz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 5, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA
Se-Hoon Lee, Shun Lu, Hidetoshi Hayashi, et al.
Page
of 52